by Jordana Choucair | Nov 18, 2021 | Payers
The Biden administration released an interim final rule that will require health insurers and employers to report a plethora of drug data to the federal government. Insurers would need to disclose the 50 most expensive drugs they cover and the 25 drugs that yield the...
by Jordana Choucair | Nov 18, 2021 | Opioid/Substance Use Disorders
More than 3,300 lawsuits have been filed against drug manufacturers, distributors, and pharmacies for their role in exacerbating the country’s opioid epidemic. Recognizing that final verdicts in these legal proceedings could take years, Senior Director Tym Rourke...
by Jordana Choucair | Nov 18, 2021 | Opioid/Substance Use Disorders
Provisional data from the CDC shows that an estimated 100,306 people in the U.S. died from a drug overdose in a 12-month period ending April 2021. It’s the first time drug overdose fatalities reached six figures in a single year, and signals that the country is...
by Jordana Choucair | Nov 18, 2021 | Mental Health
At the recent National Association of Medicaid Directors conference, Vikki Wachino, former CMS Director/Deputy Administrator of the Center for Medicaid and CHIP Services, shared her thoughts about the imperative to deliver for kids’ mental health. Vikki outlined...
by Jordana Choucair | Nov 18, 2021 | Life Sciences
The CMS extended the deadline for drugmakers to comply with the Trump-era regulation requiring them to calculate the “best price” for drugs under Medicaid’s drug rebate program using discounts they offer patients. The new final rule will officially...
Recent Comments